Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, Marketbeat ...

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the ...

Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand ...